Official resource: The Manila Times
Biocare Lifesciences Inc (BLI), a Philippines based pharmaceutical company who brought the brands of Remdesivir and Favipiravir in the country last year, announced the launched of the first branded generic of Tocilizumab (Temziva) 400mg/20mL Solution for infusion.
Temziva (Tocilizumab), a treatment known as an Interleukin-6 (IL-6) receptor blocker, has received approval from the Philippines Food and Drug Administration (FDA) to treat severe Covid-19 patients with Cytokine Release Syndrome.
Tocilizumab is an Interleukin-6 (IL-6) receptor blocker that can effectively block what is known as the IL-6 signal transduction pathway, which plays an important role in Cytokine Release Syndrome.
“The availability of tocilizumab in the Philippines is another milestone in the fight against Coid-19,” said Dileep Tiwari, managing director. “As a healthcare company, it is our responsibility to make available products of the highest standards and quality to address high unmet needs among our patients.”
“We are honored to be able to make available tocilizumab in the Philippines, to serve as a new possibility for treatment of severe Covid-19 patients who have not already had access to life-saving drugs. With this development, we hope to make tocilizumab available as widely as possible to help save lives,” said Suchet Rastogi from SRS.
Tocilizumab is approved as a Drug Product for Emergency Use Only (DEU). Tocilizumab will be available in over 200 hospitals in the Philippines. SRS Life Sciences holds the registration for tocilizumab in the Philippines, while AryoGen will produce the therapy, and Biocare Lifesciences will distribute the therapy to hospitals in the Philippines.
